The latest market report published by Credence Research, Inc. “Global Cell Line Development Market: Growth, Future Prospects, and Competitive Analysis, 2017 – 2030”. The global cell line development market generated revenue of around USD 5.3 billion in 2022 and is expected to grow a CAGR of over 13.50% over the forecast period from 2023 to 2030 to reach around USD 12.86 billion in 2030.
Growing adoption of regenerative medicines drives cell line development market growth. Regenerative medicines can potentially replace or heal tissues and organs damaged owing to several factors, such as disease, age, or trauma; they also assist in normalizing congenital disabilities. Over the last quarter of a century, a tissue engineering industry has emerged, which has now grown into the broader area of regenerative medicines. Regenerative medicines are a rapidly expanding interdisciplinary field involving engineering sciences to develop clinical therapies for maintaining, repairing, replacing, and enhancing biological functions. Cell line development is a critical and invariable part of this field as it helps understand how to treat various medical conditions, from broken bones to neurodegenerative diseases.
The global cell line development market is bifurcated into the product, source, cell line type, application, and geography. Based on product, the market is categorized into reagents & media, equipment & accessories, and consumables. On the basis of the source, the global market is segmented into mammalian cell lines and non-mammalian cell lines. On the basis of the cell line type, the global market is segmented into recombinant cell lines, continuous cell lines, hybridomas, and primary cell lines. Based on the application, the global market is segmented into bioproduction, drug discovery, toxicity testing, vaccines, tissue engineering, research, and others. Based on geography, the market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.
In 2022, North America dominated the global cell line development market, accounting for a major market revenue share value. This is majorly owing to the high incidence of chronic diseases, such as cancers, along with the increased investment in research and development activities by the major players. According to the American Cancer Society Facts and Figure 2021, the number of cancer deaths and new cases estimated for 2021 was 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the US.
The Cell Line Development Market major players analysis is a crucial aspect of understanding the growth potential of this industry. In recent years, there has been a significant surge in demand for cell line development services due to their numerous applications across diverse fields such as biotechnology, pharmaceuticals, and research institutions. The analysis considers key market players that drive the competitive landscape of this market segment. These players include Thermo Fisher Scientific Inc., Sartorius AG, GE Healthcare, Merck KGaA (Sigma-Aldrich Corporation), and Lonza Group AG.
The cell line development market has been experiencing significant growth worldwide due to several factors.
- One of the primary drivers of market growth is the increasing demand for cell-based therapies and biologics. Cell-based therapies and biologics have gained popularity in recent years due to their effectiveness in treating various diseases such as cancer, autoimmune disorders, and genetic disorders. These therapies require the use of well-characterized and validated cell lines for the production of biologics and other cell-based products.
- Additionally, the growing prevalence of chronic diseases and the aging population have led to an increase in demand for cell-based therapies and biologics. As a result, there has been a growing need for the development of stable and high-quality cell lines that can be used for the production of these therapies.
- Moreover, the development of new technologies and techniques for cell line development has also played a role in the growth of the market. Advances in gene editing technologies, such as CRISPR-Cas9, have made it easier and more efficient to modify cells and create stable cell lines with desired properties.
- Furthermore, the increasing investments in research and development of cell-based therapies and biologics by biopharmaceutical companies and academic institutions have also contributed to the growth of the cell line development market. These investments have led to the development of new and improved cell lines that can be used for the production of biologics and other cell-based products.
- Overall, the cell line development market is expected to continue experiencing significant growth worldwide due to the increasing demand for cell-based therapies and biologics, the growing prevalence of chronic diseases, the development of new technologies and techniques for cell line development, and the increasing investments in research and development of cell-based therapies and biologics.
Why Buy This Report-
- The report delivers a qualitative and quantitative analysis of the global cell line development market by segments, current trends, drivers, restraints, challenges, opportunities, and market dynamics with the historical period from 2018-2021, base year- 2022, and forecast period 2023-2030.
- The report includes information connected to the competitive landscape, like how the essential players in the market are working at a global, regional, and country level.
- In-depth analysis of the global cell line development market segmentation based on product, source, application, and cell line type.
- Prominent countries in each region with their import/export statistics
- The global cell line development market report also includes studying the global, regional, and country levels, along with key market trends, significant players analysis, market growth strategies, and key application areas.
Browse Our Blog: https://www.credenceresearch.com/report/cell-line-development-market
Related Report: https://www.credenceresearch.com/report/biomarkers-market